Fanghou Inc.和创新性生物学团队,利用AI改善中国糖尿病和肥胖症的护理。 Fangzhou Inc. and Innovent Biologics team up to improve diabetes and obesity care in China using AI.

Fangzhou Inc.和创新性生物学合作,将AI驱动的保健服务与中国新的糖尿病和肥胖症治疗相结合。 Fangzhou Inc. and Innovent Biologics have partnered to merge AI-driven healthcare services with new treatments for diabetes and obesity in China. 这一协作旨在提供个性化、全天候的数字化护理,并改善对新陈代谢疾病的患者教育。 This collaboration aims to offer personalized, round-the-clock digital care and improve patient education for metabolic diseases. 该伙伴关系标志着通过先进技术和创新疗法加强慢性病管理的一个步骤。 The partnership marks a step towards enhancing chronic disease management through advanced technology and innovative therapies.